Active Stocks in Focus: Johnson & Johnson (NYSE:JNJ), Can-Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) 

Johnson & Johnson (NYSE:JNJ)‘s shares increased 0.14% to $93.26.


Johnson & Johnson, together with its associates, explores and creates, makes, and offers different items in the medicinal services field around the world. It works in three sections: Consumer, Pharmaceutical, and Medical Devices.

Johnson & Johnson (JNJ) will have a telephone call for financial specialists at 8:30 a.m. (Eastern Time) on Tuesday, Oct. thirteenth, to audit second from last quarter results. Gary Pruden, Worldwide Chairman, Medical Devices; Dominic Caruso, Vice President, Finance and Chief Financial Officer and Louise Mehrotra, Vice President, Investor Relations, will have the call.

Toward the end of Tuesday’s exchange, Can-Fite Biopharma Ltd (ADR) (NYSEMKT:CANF)‘s shares surged 9.86% to $4.01.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical organization, grows little particle helpful items for the treatment of immune system incendiary, oncological, and ophthalmic illnesses. It offers CF101, which has fulfilled Phase II/III clinical trials for the treatment of psoriasis; achieved Phase II clinical trials for the treatment of rheumatoid joint pain; finished Phase I clinical study for the treatment of osteoarthritis; and achieved Phase I concentrate on for the treatment of uveitis, notwithstanding is in Phase II clinical trials for the treatment of glaucoma or related disorders of visual hypertension.

Can-Fite BioPharma Ltd. (CANF) a biotechnology organization with a pipeline of restrictive little atom tranquilizes that address provocative and malignancy ailments, as of late pronounced the U.S. Sustenance and Drug Administration (FDA) has allowed the Company’s medication competitor CF102 Fast Track assignment as a second line treatment for hepatocellular carcinoma (HCC), the most widely recognized type of liver disease. CF102 had officially gotten the FDA’s Orphan Drug assignment.

Can-Fite is in a matter of seconds directing a Phase II study for this sign in the U.S., Europe and Israel. The randomized, twofold visually impaired, placebo controlled study is unsurprising to finish enlistment before the first’s end a large portion of 2016 in 78 patients with Child-Pugh Class B cirrhosis who fizzled the main FDA affirmed medication available, Nexavar® (sorafenib). Patients are dealt with twice day by day with 25 mg of oral CF102, which has been observed to be the most useful measurements in Can-Fite’s prior Phase I/II study bringing about the longest general survival time, with incredible wellbeing results.

Notes to the Stakeholders:

This article is the intellectual property of The purpose of penning down this article has been just to share information. Moreover, it is firmly believed that all the information that are revealed in this article are from reliable sources, however, we do not make any representations or warranties whatsoever of any kind, express or implied, as far as the completeness, accurateness, or reliability with respect to this article is concerned.

All the respectable visitors to this website are kindly advised to conduct their own independent research into individual stocks prior to making a purchase decision.

This article contains an advanced information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as well as statements regarding the forseeable frequent growth of the market for the corporation’s products, the corporation’s capability to fund its capital requirement in the close-to term and in the long term; pricing pressures; etc.

Furthermore, any statement that expresses or involves discussions with respect to forecast, expectations, beliefs, strategy, projection, objectives, aims, assumption, or future events or performance may be forward looking statements. In addition, the forward-looking statements are wholly and solely based upon expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. An easy way to identify the forward looking statements is through the use of such words as be expecting, will, foresee, guess, considered, or by statements that indicates certain actions may, could, should/might occur.


About the Author

Tanya Jones
Tanya is a senior reporter for JBH News Sports & Tech section. She graduated from York College, City University of New York in 2012.